Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device
NCT00283764
Last updated date
ABOUT THIS STUDY
Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Open-Angle Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
18 + years
Inclusion Criteria
Show details
- Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes
Exclusion Criteria
Show details
- History of closed/barely open anterior chamber angle or a history of angle closure
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Open-Angle Glaucoma, Ocular HypertensionCorneal Versus Conjunctival Delivery Using a Delivery Device
NCT00143429
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Open-Angle Glaucoma, Ocular HypertensionA Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
NCT00934089
- Cypress, California
- Garden Grove, California
- Gardena, California
- Long Beach, California
- Los Angeles, California
- Los Angeles, California
- Newport Beach, California
- Pasadena, California
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Open-Angle Glaucoma, Ocular HypertensionDistribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
NCT00334750
- Calgary, Alberta
- Edmonton, Alberta
- Edmonton, Alberta
- Nanaimo, British Columbia
- Vancouver, British Columbia
- Williams Lake, British Columbia
- Winnipeg, Manitoba
- Sydney, Nova Scotia
- Brampton, Ontario
- Hamilton, Ontario
- London, Ontario
- Mississauga, Ontario
- Oakville, Ontario
- Oakville, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Sherbrooke, Quebec
- Saskatoon, Saskatchewan
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Open-Angle Glaucoma, Ocular HypertensionA Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
NCT00647101
- Albi,
- Ambert,
- Amboise,
- Angers,
- Antibes,
- Aubenas,
- Belfort,
- Bergerac,
- Bernay,
- Bethune,
- Beziers,
- Blagnac,
- Bordeaux,
- Bordeaux,
- Bougival,
- Boulogne-Billancourt,
- Brest,
- Bry Sur Marne,
- Carentan,
- Cenon,
- Chamalieres,
- Chantilly,
- Chartres,
- Chateaubriant,
- Chateaulin,
- Clermont-Ferrand,
- Condom,
- Coulommiers,
- Courbevoie,
- Creil,
- Deauville,
- Deuil la Barre,
- Douai,
- Draveil,
- Enghien Les Bains,
- Epernay,
- Fontaine,
- Frejus,
- Gennevilliers,
- Gradignan,
- Grasse,
- Grasse,
- Grenoble,
- Grenoble,
- Guingamp,
- Haguenau,
- Herblay,
- Hyeres,
- Issy Les Moulineaux,
- Ivry Sur Seine,
- Jarville La Malgrange,
- Joigny,
- Juvisy Sur Orge,
- La Rochelle,
- La Talaudiere,
- La Trinite,
- Landerneau,
- Langon,
- Lannion,
- Laon,
- Le Creuzot,
- Le Havre,
- Le Mans,
- Le peage de Rousillon,
- Le Quesnoy,
- Lesneven,
- Lille,
- Livry Gargan,
- Lunel,
- Luneville,
- Luxeuil les Bains,
- Lyon,
- Lyon,
- Lyon,
- Lyon,
- Maisons Laffitte,
- Marcq en Baroeul,
- Marignanne,
- Marseille,
- Marseille,
- Marseille,
- MArseille,
- Marseille,
- Meyzieu,
- Montauban,
- Montceau Les Mines,
- Montpellier,
- Mulhouse,
- Nantes,
- Nice,
- Nice,
- Nimes Cedex 2,
- Nimes,
- Niort,
- Nogent Sur Marne,
- Noyon,
- Orleans,
- Oullins,
- Pantin,
- Paray le Monial,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Pauillac,
- Pau,
- Perigueux,
- Perros Girec,
- Pezenas,
- Poissy,
- Poitiers,
- Pont de Cheruy,
- Pornic,
- Port De Bouc,
- Quimper,
- Reims,
- Rochefort,
- Romilly sur Seine,
- Saint Die des Vosges,
- Saint Etienne,
- Saint Gaudens,
- Saint Savine,
- Saintes,
- Salon de Provence,
- Sartrouville,
- Sens,
- Sessiney Pariset,
- Sete,
- Soissons,
- St Chamond,
- St Etienne,
- St Michel Sur Orge,
- St. Brieuc,
- St. Lo,
- Strasbourg,
- Strasbourg,
- Suresnes,
- Talence,
- Thiers,
- Toulon,
- Toulouse,
- Toulouse,
- Tourcoing,
- Tournefeuille,
- Tours,
- Trelissac,
- Tremblay en France,
- Triel Sur Seine,
- Troyes,
- Valenciennes,
- Vannes,
- Vauvert,
- Veauche,
- Velaux,
- Vendargues,
- Venissieux Cedex,
- Viarmes,
- Vienne,
- Villeneuve D'Ascq,
- Villeneuve la Garenne,
- Villeneuve Saint Georges,
- Villeparisis,
- Villepinte,
- Villiers Le Bel,
- Vizille,
- Voiron,
- Wattrelos,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device | |||
Official Title ICMJE | A Phase 3, 12-Week, Parallel-Design Study Comparing The Safety, Efficacy, and Ease Of Use Of Xalatan When Self-Administered By Subjects With Open-Angle Glaucoma Or Ocular Hypertension Using Either A Conventional Dropper Bottle Or A Forced-Flow Delivery Device | |||
Brief Summary | Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE | Drug: Xalatan | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Withdrawn | |||
Actual Enrollment ICMJE | 0 | |||
Original Enrollment ICMJE | 712 | |||
Study Completion Date ICMJE | Not Provided | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00283764 | |||
Other Study ID Numbers ICMJE | A6111086 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
Study Sponsor ICMJE | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | March 2015 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |